SG10201914054SA - Isoquinolin-3-yl carboxamides and preparation and use thereof - Google Patents

Isoquinolin-3-yl carboxamides and preparation and use thereof

Info

Publication number
SG10201914054SA
SG10201914054SA SG10201914054SA SG10201914054SA SG10201914054SA SG 10201914054S A SG10201914054S A SG 10201914054SA SG 10201914054S A SG10201914054S A SG 10201914054SA SG 10201914054S A SG10201914054S A SG 10201914054SA SG 10201914054S A SG10201914054S A SG 10201914054SA
Authority
SG
Singapore
Prior art keywords
isoquinolin
carboxamides
preparation
Prior art date
Application number
SG10201914054SA
Other languages
English (en)
Inventor
Sunil Kumar Kc
Chi Ching Mak
Brian Eastman
Jianguo Cao
Venkataiah Bollu
Gopi Kumar Mittapalli
Chandramouli Chiruta
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of SG10201914054SA publication Critical patent/SG10201914054SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
SG10201914054SA 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof SG10201914054SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662328255P 2016-04-27 2016-04-27

Publications (1)

Publication Number Publication Date
SG10201914054SA true SG10201914054SA (en) 2020-03-30

Family

ID=60157337

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809301YA SG11201809301YA (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof
SG10201914054SA SG10201914054SA (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201809301YA SG11201809301YA (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Country Status (28)

Country Link
US (7) US10106527B2 (es)
EP (2) EP3892276A1 (es)
JP (1) JP6993985B2 (es)
KR (1) KR102374844B1 (es)
CN (1) CN109310690B (es)
AR (1) AR108325A1 (es)
AU (1) AU2017258193B2 (es)
CA (1) CA3022002A1 (es)
CL (2) CL2018003065A1 (es)
CO (1) CO2018012299A2 (es)
CY (1) CY1124302T1 (es)
DK (1) DK3448386T3 (es)
ES (1) ES2865374T3 (es)
HR (1) HRP20210607T1 (es)
HU (1) HUE054103T2 (es)
IL (1) IL262470B (es)
LT (1) LT3448386T (es)
MA (1) MA43619B1 (es)
MD (1) MD3448386T2 (es)
MX (1) MX2018013174A (es)
PE (1) PE20190326A1 (es)
PH (1) PH12018502258A1 (es)
PL (1) PL3448386T3 (es)
PT (1) PT3448386T (es)
RS (1) RS61879B1 (es)
SG (2) SG11201809301YA (es)
SI (1) SI3448386T1 (es)
WO (1) WO2017189829A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CN108472290A (zh) 2015-11-06 2018-08-31 萨穆梅德有限公司 治疗骨关节炎
WO2017100726A1 (en) 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
AR108325A1 (es) * 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
US10604514B2 (en) * 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
WO2019084497A1 (en) 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
WO2019089835A1 (en) * 2017-10-31 2019-05-09 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
CN112334450A (zh) 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt
JP2021529161A (ja) 2018-06-18 2021-10-28 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレーターとしてのピリジニルピラゾール
CN112566901A (zh) 2018-06-18 2021-03-26 詹森药业有限公司 作为RORγt的调节剂的苯基取代的吡唑类
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2020150552A2 (en) 2019-01-17 2020-07-23 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
WO2021007378A1 (en) * 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
JPWO2021235293A1 (es) * 2020-05-20 2021-11-25
WO2022089454A1 (zh) * 2020-10-28 2022-05-05 杭州阿诺生物医药科技有限公司 一种高活性Wnt通路抑制剂化合物
TW202321244A (zh) * 2021-07-26 2023-06-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
TW202334157A (zh) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Wnt通路抑制劑化合物
WO2024022365A1 (zh) * 2022-07-28 2024-02-01 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
KR101204247B1 (ko) 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-이치환된 1h-피라졸 화합물 및 그의 시클린 의존성키나제 (cdk) 및 글리코겐 합성효소 키나제-3(gsk-3) 조정제로서 용도
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
EP1861161A4 (en) 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
CA2696321A1 (en) 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2009085226A2 (en) 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibitors of cdc2-like kinases (clks) and methods of use thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
CN105037355B (zh) 2009-08-10 2017-06-06 萨穆梅德有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
WO2011019648A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
US7998878B2 (en) 2009-11-20 2011-08-16 Eastman Kodak Company Method for selective deposition and devices
JP5822844B2 (ja) 2009-12-21 2015-11-24 サミュメッド リミテッド ライアビリティ カンパニー 1H−ピラゾロ[3,4−b]ピリジンおよびその治療的使用
MX2012010666A (es) 2010-03-31 2012-10-05 Actelion Pharmaceuticals Ltd Derivados de isoquinolin-3-ilurea antibacterianos.
AR084280A1 (es) * 2010-12-17 2013-05-02 Hoffmann La Roche Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos
CN102558173B (zh) * 2010-12-31 2015-05-20 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
SG10201914121YA (en) * 2011-09-14 2020-03-30 Samumed Llc Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
PE20170127A1 (es) 2014-03-20 2017-03-30 Samumed Llc Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP4086257A1 (en) 2016-09-30 2022-11-09 SRI International Dual clk/cdk1 inhibitors for cancer treatment
EP3813826A4 (en) 2018-06-26 2022-07-06 BioSplice Therapeutics, Inc. METHOD OF TREATMENT OF CANCER USING A CLK INHIBITOR
WO2020150545A1 (en) 2019-01-17 2020-07-23 Samumed, Llc Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway

Also Published As

Publication number Publication date
MD3448386T2 (ro) 2022-05-31
EP3448386B1 (en) 2021-03-03
WO2017189829A1 (en) 2017-11-02
US20220332698A1 (en) 2022-10-20
SI3448386T1 (sl) 2021-08-31
CL2019001343A1 (es) 2019-10-11
ES2865374T3 (es) 2021-10-15
US10947217B2 (en) 2021-03-16
US10100038B2 (en) 2018-10-16
US10544128B2 (en) 2020-01-28
JP6993985B2 (ja) 2022-01-14
US20180093970A1 (en) 2018-04-05
US11548872B2 (en) 2023-01-10
CL2018003065A1 (es) 2019-02-01
JP2019514938A (ja) 2019-06-06
US20230286945A1 (en) 2023-09-14
US20170313682A1 (en) 2017-11-02
MX2018013174A (es) 2019-02-13
CA3022002A1 (en) 2017-11-02
DK3448386T3 (da) 2021-04-26
CN109310690A (zh) 2019-02-05
PT3448386T (pt) 2021-04-22
HUE054103T2 (hu) 2021-08-30
AU2017258193A1 (en) 2018-11-15
PH12018502258A1 (en) 2019-09-16
RS61879B1 (sr) 2021-06-30
RU2018141395A (ru) 2020-05-28
KR20190014505A (ko) 2019-02-12
US20180155323A1 (en) 2018-06-07
CN109310690B (zh) 2021-09-07
US10106527B2 (en) 2018-10-23
HRP20210607T1 (hr) 2021-06-25
LT3448386T (lt) 2021-06-25
MA43619B1 (fr) 2020-10-28
EP3448386A4 (en) 2019-12-18
PE20190326A1 (es) 2019-03-05
EP3892276A1 (en) 2021-10-13
AR108325A1 (es) 2018-08-08
EP3448386A1 (en) 2019-03-06
RU2018141395A3 (es) 2020-08-13
MA43619A1 (fr) 2019-10-31
BR112018072169A2 (pt) 2019-02-12
KR102374844B1 (ko) 2022-03-16
IL262470A (en) 2018-12-31
CO2018012299A2 (es) 2019-04-30
AU2017258193B2 (en) 2021-06-03
US20190233396A1 (en) 2019-08-01
US20200299263A1 (en) 2020-09-24
CY1124302T1 (el) 2022-07-22
BR112018072169A8 (pt) 2022-11-08
PL3448386T3 (pl) 2021-11-02
IL262470B (en) 2021-12-01
SG11201809301YA (en) 2018-11-29
US9951048B1 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
IL262470A (en) Isoquinolin-3-yl carboxamides, their preparation and uses
IL262495A (en) Isoquinolin-3-yl carboxamides and their preparation and uses
EP3302442A4 (en) PHARMACEUTICAL FORM AND USE THEREOF
SI3235830T1 (sl) Proteinski kompleks interlevkina 15 in njegove uporabe
IL264813B (en) 2-oxo-imidazopyridines and their use
EP3124741A4 (en) Self-suspending proppant and preparation and use thereof
HK1252567A1 (zh) 被取代的苯甲酰胺和其使用方法
GB2582410B (en) DDX24 mutations and use thereof
SG10202010420TA (en) Patient interface and aspects thereof
HK1258470A1 (zh) 血液製備和圖譜分析
PL3398598T3 (pl) Pochodne sulfonoamidowe oraz sposoby ich wytwarzania i zastosowanie
IL250112B (en) Aqueous composition containing paracetamol and ibuprofen
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
IL264403A (en) Vortioxetine analogue and use and preparation thereof
HK1245113A1 (zh) 藥物組合物及其用途
GB201607609D0 (en) Catalyst and use thereof
EP3563861C0 (en) GINSENG NANOPARTICLES AND THE PRODUCTION AND USE THEREOF
GB201705960D0 (en) Novel ligand and use thereof
GB201509977D0 (en) Dispensers and methods of use thereof
GB201420805D0 (en) Ligatures and use thereof
GB2545167B (en) Cloches and use thereof
GB201620841D0 (en) Catalyst and use thereof